[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sham-controlled\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sham-controlled":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100652849","stimulation-evaluation-for-neuromodulation-sensory-effects-100652849",false,"NCT07777991","Stimulation Evaluation for Neuromodulation Sensory Effects","SENSE","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Self-reported good general health, as assessed by study personnel.\n\nExclusion Criteria:\n\n1. Non-English speaking\n2. History of epilepsy, seizure disorder, unprovoked seizure, or status epilepticus.\n3. History of febrile seizures beyond early childhood\n4. Current use of medications known to substantially lower seizure threshold, including but not limited to certain antidepressants, antipsychotics, stimulants,\n5. History of significant neurological disease, including stroke, traumatic brain injury with loss of consciousness, brain tumor, neurodegenerative disease, multiple sclerosis, or other clinically significant neurological disorders.\n6. Prior intracranial neurosurgical procedure or implanted neurostimulation device.\n7. Presence of an implanted electrical, neurostimulation, cardiac rhythm management, or other active implanted medical device.\n8. Significant scalp abnormalities that may interfere with electrode placement, including active skin disease, open wounds, infection, or severe dermatologic conditions involving the scalp.\n9. Current diagnosis of a major psychiatric disorder that, in the opinion of the investigator, may interfere with study participation or interpretation of study results.\n10. History of severe depression associated with suicidal ideation, suicidal behavior, suicide attempt, psychiatric hospitalization for suicidality.\n11. Current suicidal ideation or behavior, as determined by participant self-report.\n12. Current substance abuse and\u002For alcohol dependence that may impair the participant's ability to safely complete study procedures.\n13. Pregnant or breastfeeding.\n14. Participation in another investigational drug, biologic, or device study within 30 days prior to enrollment, unless approved by the investigator and sponsor.\n15. History of migraine with aura, photosensitive migraine, recurrent phosphenes, visually induced neurological symptoms, or other conditions associated with heightened susceptibility to visual sensory phenomena, as determined by the investigator.\n16. History of recurrent syncope, unexplained loss of consciousness, vasovagal episodes requiring medical intervention, or other conditions associated with increased risk of fainting during medical procedures or sensory stimulation, as determined by the investigator.",true,"ALL","18 Years","85 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn how healthy adults experience low-level electrical stimulation delivered through the study device. This study is not intended to treat a medical condition.\n\nThe main questions it aims to answer are:\n\nIs the study stimulation comfortable and well tolerated? What sensations do participants notice during stimulation? Can participants tell the difference between active stimulation and sham stimulation?\n\nResearchers will compare active stimulation with sham stimulation. Sham stimulation uses the same study procedures but does not deliver the study stimulation. This comparison will help researchers understand whether sensations are caused by stimulation rather than the study setting or expectations.\n\nParticipants will:\n\nReceive brief sessions of active and sham stimulation using the study device. Report sensations, discomfort, or other effects during and after each session. Complete questionnaires or other assessments about their experience with stimulation.\n\nThe information from this study will help researchers select stimulation settings and procedures for future studies.",[28,29,30],"Sham-controlled","Healthy Adult Participants","Electric Stimulation",[32,33,34,35,36,28,37],"Healthy volunteers","Electrical stimulation","Intersectional Short-Pulse (ISP) stimulation","Neuromodulation","Sensory effects","Noninvasive brain stimulation","NOT_YET_RECRUITING","2026-08-18",{"date":41,"type":42},"2026-08-21","ACTUAL",{"date":44,"type":22},"2026-09-01",{"date":46,"type":22},"2027-09-01",{"name":48,"class":49},"Adraxe Corp.","INDUSTRY",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100638885","extracorporeal-shock-wave-therapy-in-lower-extremity-lymphedema-100638885","NCT07626645","Extracorporeal Shock Wave Therapy in Lower Extremity Lymphedema","Efficacy of Extracorporeal Shock Wave Therapy (ESWT) in Lower Extremity Lymphedema: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 to 80 years\n* Clinical diagnosis of lower extremity lymphedema established at least 6 months prior to enrollment\n* Completion of at least one cycle of CDT Phase 1 (intensive decongestive phase) within the preceding six months\n* Currently in CDT Phase 2 (maintenance phase) with active use of compression garments\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Active chemotherapy or radiotherapy\n* Active infection\n* Lower extremity vascular diseases including deep vein thrombosis or arterial insufficiency\n* Presence of a cardiac pacemaker\n* Pregnancy\n* Bleeding disorders","80 Years",{"count":59,"type":22},36,[25],"Lower extremity lymphedema is a chronic and progressive condition associated with significant functional impairment and reduced quality of life. The current gold-standard treatment is Complex Decongestive Therapy (CDT); however, a substantial proportion of patients continue to experience persistent symptoms during the maintenance phase. This prospective, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effectiveness of Extracorporeal Shock Wave Therapy (ESWT) as an adjunct to standard CDT maintenance therapy in patients with lower extremity lymphedema. Participants will be randomly allocated to either an active ESWT group or a sham ESWT group, with both groups continuing standard CDT maintenance throughout the study. ESWT will be administered twice weekly for five sessions. Changes in limb volume, skin thickness and subcutaneous tissue thickness assessed by ultrasonography, pain, functional status, and quality of life will be evaluated at baseline, after treatment, and at one-month follow-up.",[63,64,65,28,66],"Lymphedema, Lower Limb","Extracorporeal Shock Wave Therapy","Edema Leg","Placebo Control Design",[68,69,70,71,72,73,74],"Lower Extremity Lymphedema","Extracorporeal Shock Wave Therapy (ESWT)","Complex Decongestive Therapy (CDT)","Limb Volume","Ultrasonography","skin and subcutaneous tissue thickness","Quality of Life","2026-06-02",{"date":77,"type":42},"2026-06-04",{"date":79,"type":22},"2026-06-22",{"date":81,"type":22},"2027-02-01",{"name":83,"class":84},"Gazi University","OTHER",1]